Expression level of lncRNA MIR210HG in high-grade serous ovarian cancer tissues and its correlation with clinicopathological features and prognosis
TL;DR
MIR210HG expression exhibited survival associations based on TP53 status, suggesting biomarker potential for HGSOC and is significantly upregulated in HGSOC and is associated with clinical stage, lymph node metastasis, and ascites.
Abstract
To investigate long non-coding RNA (lncRNA) MIR210HG expression in high-grade serous ovarian cancer (HGSOC) and its correlation with clinicopathological features, clinical outcomes, and prognosis. Tissue samples were collected from 84 patients with HGSOC undergoing surgical treatment at the Affiliated Hospital of Qingdao University from 2019 to 2021. Fifty-seven patients undergoing total hysterectomy and bilateral adnexectomy resection for uterine fibroids and adenomyosis during the same period were also included. MIR210HG expression was detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Univariate and multivariate logistic regression analyses were used to assess correlation with advanced FIGO stage and clinical outcomes. The Kaplan-Meier plotter was used to predict the correlation between MIR210HG expression and prognosis, considering pathological classification, clinical stage, and TP53 status. MIR210HG expression was significantly upregulated in HGSOC compared to normal ovarian and fallopian tube tissues. MIR210HG expression was moderately and weakly correlated with CA125 ( r = 0.515, P < 0.001) and HE4 levels ( r = 0.325, P = 0.001), respectively. Advanced clinical stage was associated with higher MIR210HG expression. Patients with lymph node metastasis and ascites also exhibited higher MIR210HG expression ( P < 0.05). MIR210HG was associated with FIGO stage, while CA125 ≤ 35 U/ml and FIGO stage II were independent protective factors for composite poor clinical outcomes. Patients with low MIR210HG expression had a significantly longer 5-year progression-free survival (PFS) compared to those with high expression. What’s more, MIR210HG expression was significantly correlated with both 5-year PFS and overall survival (OS) in TP53-mutant patients, as opposed to only OS in TP53 wild-type patients. MIR210HG expression is significantly upregulated in HGSOC and is associated with clinical stage, lymph node metastasis, and ascites. MIR210HG expression exhibited survival associations based on TP53 status, suggesting biomarker potential for HGSOC.